This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schiller, J. T. Articles by Lowy, D. R. Search for Related Content PubMed PubMed Citation Articles by Schiller, J. T. Articles by Lowy, D. R. Related Collections Review Epidemiology and Prevention Epidemiology and Prevention: Chemoprevention Clinical Intervention: Health Policy

Prospects for Cervical Cancer Prevention by Human Papillomavirus Vaccination

Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland

Requests for reprints: John T. Schiller, NIH, Building 37, Room 4106, Bethesda, MD 20892. Phone: 301-594-2715; Fax: 301-480-5322; E-mail: schillej{at}dc37a.nci.nih.gov.

Recent clinical trials in young women have shown that subunit vaccines based on human papillomavirus (HPV) 16 and HPV18 L1 virus-like particles are 100% effective in short-term prevention of persistent cervical infection and of cervical dysplasia by these major oncogenic types. These remarkable efficacy results, together with an excellent safety profile in thousands of vaccinated women, have led to the HPV prophylactic vaccine from one manufacturer having now been licensed for commercial use and the expectation that the vaccine from a second manufacturer will be approved in the near future. These vaccines seem to have great potential for reducing cervical cancer deaths and treatments to remove premalignant cervical lesions. However, before their public health effect can be fully estimated, several issues must be addressed. These include duration of protection, degree of cross-protection against nonvaccine types, efficacy in men, and vaccine availability to economically disadvantaged women. (Cancer Res 2006; 66(21): 10229-32)

This article has been cited by other articles:

				R. T. Javier and J. S. Butel The History of Tumor Virology Cancer Res., October 1, 2008; 68(19): 7693 - 7706. [Abstract] [Full Text] [PDF]

				M. Bellon and C. Nicot Regulation of Telomerase and Telomeres: Human Tumor Viruses Take Control J Natl Cancer Inst, January 16, 2008; 100(2): 98 - 108. [Abstract] [Full Text] [PDF]

				G. G. Kenter, M. J.P. Welters, A.R. P.M. Valentijn, M. J.G. Lowik, D. M.A. Berends-van der Meer, A. P.G. Vloon, J. W. Drijfhout, A. R. Wafelman, J. Oostendorp, G. J. Fleuren, et al. Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity Clin. Cancer Res., January 1, 2008; 14(1): 169 - 177. [Abstract] [Full Text] [PDF]

				J. K. Chan and J. S. Berek Impact of the Human Papilloma Vaccine on Cervical Cancer J. Clin. Oncol., July 10, 2007; 25(20): 2975 - 2982. [Abstract] [Full Text] [PDF]

				R W Peeling, K K Holmes, D Mabey, and A Ronald Rapid tests for sexually transmitted infections (STIs): the way forward Sex Transm Inf, December 1, 2006; 82(suppl_5): v1 - v6. [Abstract] [Full Text] [PDF]